China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

SSZSE:300294
13.25
CNY
-0.04
(-0.30%)
-0.34EPS
7.53BMarket Cap
Mar 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.72
1.29
1.57
3.55
3.65
5.65
6.48
5.89
6.08
5.49
5.25
3.45
4.02
2.84
Basic EPS, GAAP
0.24
0.31
0.44
1.02
0.89
1.11
1
0.61
0.79
0.86
0.47
0.79
0.22
-0.33
Free Cash Flow per Basic Share
0.17
0.22
-0.04
-0.38
-0.65
-0.19
-0.48
1.35
2.93
0.91
1.1
0.2
-0.93
- -
Dividend per Share
0.11
0.11
0.14
0.21
0.1
0.24
0.22
0.23
0.11
0.17
0.27
0.46
0.31
0.07
Book Value per Share
2.32
2.52
4.67
5.22
6.05
8.55
9.03
9.48
13.35
14.25
14.52
14.85
14.75
14.77
Tangible Book Value per Share
1.85
2.05
3.17
3.7
4
6.47
6.85
7.22
11.52
12.24
13.73
11.66
12.3
12.46
Basic Weighted Avg Shares
340
340
345
267
401
423
426
426
436
503
505
503
512
504
Sales/Revenue/Turnover
245
438
543
947
1,461
2,388
2,761
2,513
2,651
2,759
2,652
1,735
2,059
1,432
Operating Margin (%)
31.31
28.51
29.79
33.43
28.42
24.14
19.53
12.79
17.62
18.81
20.96
26.8
16.61
5.08
Depreciation Expense
19
27
30
44
46
55
83
83
99
97
99
103
152
- -
Net Income, GAAP
82
104
152
272
357
469
426
260
345
432
237
397
113
-168
Effective Tax Rate (%)
15.75
15.23
15.46
15.42
15.25
15.23
14.98
16.11
19.15
16.26
29.84
16.99
- -
- -
Profit Margin (%)
33.6
23.8
27.95
28.74
24.42
19.65
15.43
10.35
13
15.67
8.95
22.88
5.47
-11.73
Working Capital
468
516
831
761
1,038
2,240
2,096
2,051
5,015
5,368
5,971
4,308
4,200
4,375
LT Debt
- -
- -
22
22
450
450
269
60
33
10
24
7
60
68
Total Equity
847
924
1,908
2,132
2,484
3,771
3,989
4,192
6,920
7,285
7,321
7,488
7,439
7,450
Return on Invested Capital (%)
9.83
12.25
11.21
13.23
13.84
12.83
9.73
6.11
6.22
6.22
3.39
5.33
- -
- -
Return on Capital (%)
10.32
10.54
9.56
12.99
13.53
12.82
9.71
5.75
5.91
5.88
3.1
5.36
- -
- -
Return on Common Equity (%)
10.68
12.62
11.11
13.71
15.78
15.31
11.19
6.49
6.3
6.17
3.27
5.36
1.51
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
6
6
LT Borrowings
58
58
58
LT Finance Leases
11
10
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
504
504
504
Market Capitalization
9,359
7,181
7,533

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,954
5,012
5,037
Cash, Cash Equivalents & STI
2,768
2,772
2,786
Accounts Receivable, Net
797
783
641
Inventories
1,029
1,021
1,114
Total Current Liabilities
785
699
662
Payables & Accruals
- -
- -
- -
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.34%
14.49%
-0.65%
Free Cash Flow
1.41%
-113.59%
-564.91%
Net Income, GAAP
10.22%
1.69%
-71.61%
Sales/Revenue/Turnover
18.85%
-2.04%
18.69%
Total Cash Common Dividend
27.09%
26.05%
-32.71%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
448
447
349
490
1,735
2025
536
472
- -
585
2,059
2026
321
322
203
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.3
0.33
0.19
-0.03
0.79
2025
0.28
0.17
- -
-0.46
0.22
2026
0.06
0.04
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.16
0.46
2025
- -
- -
- -
- -
0.31
2026
- -
0.07
- -
- -
- -

Company Description

CEO
Yuxuan Pan
Full Time Employees
1,947
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 333, Huiquan Road Fuzhou JX China 344000
IPO Date
Feb 28, 2012
Business
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) engages in the research, development, production, and sale of blood products and related pharmaceuticals in China. The company offers a comprehensive portfolio of blood products including human blood albumin, human immunoglobulins such as intravenous human immunoglobulin and hepatitis B human immunoglobulin, rabies immunoglobulin, coagulation factors like human fibrinogen, and freeze-dried intravenous human immunoglobulin; biochemical drugs such as bone polypeptide, oxytocin, and heparin sodium; chemical medicines including diabetes treatments like metformin hydrochloride enteric-coated tablets, glimepiride tablets, pioglitazone hydrochloride dispersible tablets, and calcium dobesilate capsules, as well as anti-infective, cardiovascular, and cerebrovascular drugs; and active pharmaceutical ingredients. Founded in 1993 and headquartered in Fuzhou, Jiangxi Province, the company operates primarily in China through production bases, single plasma collection stations, and a network of member enterprises, serving medical and health markets as a key platform under China Resources Health Division. Recent developments include its restructuring and full integration into China Resources Pharmaceutical Group, solidifying its position in the biopharmaceutical sector; board appointments approved in 2025 to strengthen governance; and involvement in provincial key R&D projects in Jiangxi, alongside operational enhancements such as updates to product information disclosures for human albumin injections and procurement for plasma stations.